文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

抗病毒药物治疗COVID-19的自适应随机安慰剂对照II期试验(VIRCO):研究方案结构化摘要

An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-10-13

VIRCO是一项多中心、三盲、随机安慰剂对照II期试验,计划招募190例(每组95例)SARS-CoV-2感染者,评估法匹拉韦相比标准治疗在14天内病毒学治愈时间的疗效与安全性。主要结局为入组后14天内连续两次咽拭子(或鼻/咽联合拭子)核酸检测阴性的时间。

要点

  • 法匹拉韦组第1天1800 mg每日两次,随后800 mg每日两次共13天。
  • 主要结局为14天内病毒学治愈时间,定义为连续两次拭子核酸阴性。
  • 试验为三盲设计,按研究中心分层,社区入组者视为一个中心。

核心结论

  • 该方案旨在评估法匹拉韦相比标准治疗对COVID-19病毒学治愈时间的疗效,并评价其安全性与临床获益。

研究设计与样本

  • 多中心、三盲、随机安慰剂对照II期、双臂平行组试验,分配比1:1。
  • 计划招募190例(每组95例),首个候选抗病毒药为法匹拉韦。
  • 随机化由Alfred医院临床试验药房使用计算机生成的区组随机列表执行,每区组6例。
  • 随机化按研究中心分层,社区入组者视为一个研究中心。

关键数值与推荐

  • 纳入标准:年龄≥18岁;过去5天内核酸检测确诊SARS-CoV-2;COVID-19相关症状在5天内开始。
  • 排除标准:对研究药物已知过敏;正在参加其他抗COVID-19抗病毒治疗试验;妊娠;Child-Pugh C级严重肝功能障碍;需透析的肾功能损害。
  • 干预:法匹拉韦第1天1800 mg每日两次,随后800 mg每日两次共13天;对照为安慰剂。
  • 主要结局:入组后14天内连续两次咽拭子(或鼻/咽联合拭子)核酸检测阴性的病毒学治愈时间。

临床怎么用

  • 该方案为II期试验设计,结果尚未报告,暂不能直接指导临床用药决策。

局限性

  • 原文为研究方案摘要,未报告任何疗效或安全性结果。
  • 样本量190例,仅评估法匹拉韦一个候选抗病毒药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primary objective: To determine the efficacy of a candidate antiviral on time to virological cure compared to standard of care within 14 days of randomisation Secondary objectives: • To determine the safety of the antiviral • To determine the clinical benefit of the antiviral over placebo according to the WHO 7-point ordinal scale • To determine the clinical benefit of the antiviral over placebo on time to resolution of clinical symptoms • To determine the effect of the antiviral over placebo on biomarkers of inflammation and immune activation TRIAL DESIGN: This is a multi-centre, triple-blind, randomised placebo controlled phase II, 2-arm trial with parallel-group design with allocation ratio 1:1. PARTICIPANTS: Inclusion Criteria: • Provision of informed consent by the participant • Age ≥18 years • Confirmed SARS-CoV-2 by nucleic acid testing in the past 5 days • COVID-19 related symptom initiation within 5 days • Female patients of childbearing potential must have a negative pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment. EXCLUSION CRITERIA: • Known allergy to the study medication • Is on another clinical trial investigating an antiviral treatment for COVID-19 • Pregnancy • Patients with severe hepatic dysfunction equivalent to Grade C in the Child-Pugh classification • Patients with renal impairment requiring dialysis • Is deemed by the Investigator to be ineligible for any reason Participants will be recruited from, and the study visits will take place at Alfred Hospital, Monash Health, Austin Health in Victoria, Australia for hospitalised participants as well as recruitment in the community in participants homes for eligible people not requiring hospitalisation. INTERVENTION AND COMPARATOR: The first candidate antiviral is favipiravir Arm 1: Favipiravir 1800 mg favipiravir BD on Day 1 followed by 800 mg BD favipiravir for the next 13 days. Arm 2: Placebo MAIN OUTCOMES: Primary outcome: Time to virological cure as defined by 2 successive throat (or combined nose/throat) swabs negative for SARS-CoV-2 by nucleic acid testing during the 14 days after enrolment. RANDOMISATION: Randomisation performed at the Alfred Hospital Clinical Trials Pharmacy using computer generated block-randomisation lists with 6 participants per block. Within each block half of the participants will be randomised to the candidate antiviral and the other half to placebo. Randomisation is stratified by study site, with participants enrolled in the community considered as a study site. BLINDING (MASKING): Study participants, study investigators and the study statistician will be blinded to treatment allocation. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The study aims to recruit 190 people (95/arm) with the first candidate antiviral favipiravir TRIAL STATUS: Protocol version 2.0 Dated 31-Jul-2020. Recruitment will take place between July 2020 and December 2020. TRIAL REGISTRATION: clinicaltrials.gov NCT04445467 First posted 24-Jun-2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. McMahon JH, Lau JSY, Roney J, et al. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33050947. doi:10.1186/s13063-020-04766-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。